Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCB-Tregs (fucosylated)
- Development stage
- Phase 1
- Lead developer
- Cellenkos
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
UCB-Tregs (fucosylated) are an allogeneic cell therapy consisting of regulatory T cells (Tregs) derived from umbilical cord blood that have been expanded ex vivo and treated with the enzyme fucosyltransferase-VI (FTVI). This enzymatic modification adds fucose to the cell surface, creating sialyl Lewis X moieties on P-selectin glycoprotein ligand-1 (PSGL-1). This process is designed to enhance the cells' ability to home to inflamed tissues by increasing their binding affinity for E-selectin and P-selectin. The therapy is primarily investigated for the prevention and treatment of graft-versus-host disease (GVHD) in patients receiving allogeneic hematopoietic stem cell transplants.
- Other names
- fucosylated regulatory T cellsfucosylated UCB Tregs3rd party fucosylated UCB Tregsfucosylated umbilical cord blood-derived regulatory T cells
02
Targets
SELP (P-selectin)SELE (E-selectin)PSGL-1 (P-selectin glycoprotein ligand-1)
Beyond the preview
Go deeper on UCB-Tregs (fucosylated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCB-Tregs (fucosylated).